Price movement over the last 24 hours
Agilent Technologies Inc vs Celsius Holdings, Inc. — how do they compare? Agilent Technologies Inc trades at $128.87 (market cap $37.04B), while Celsius Holdings, Inc. trades at $30.64 (market cap $8.10B). The key difference: Agilent Technologies Inc is far larger — about 4.6× Celsius Holdings, Inc.'s market cap, and Agilent Technologies Inc pays a 0.78% dividend while Celsius Holdings, Inc. pays none. Which is the better fit depends on your goals.
| A | CELH | |
|---|---|---|
Market Cap | $37.04B | $8.10B |
Sector | Health | Consumer Staples |
52-Week High | $157.20 | $64.86 |
52-Week Low | $110.24 | $27.75 |
Enterprise Value | $38.59B | $9.98B |
Dividend Yield | 0.78% | — |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
Celsius Holdings (CELH) trades at $31.70, down 4.4% on the day, with strong analyst consensus (95.65% buy ratings) and a $53.11 price target. Recent quarters show consistent earnings beats, with Q1 2026 EPS of $0.41 beating expectations of $0.29. Revenue growth is robust, projected at $3.0B for 2026, though net margins have compressed from 17.2% in 2023 to 4.29% in 2025. Technical indicators show a bullish moving average trend but neutral oscillators, with key resistance at $34.
The outlook remains positive driven by international expansion and functional beverage demand, but risks include margin pressure, ongoing legal investigations, and high valuation multiples. The stock offers significant upside to consensus targets if growth execution continues, though investor sentiment is tempered by near-term profitability concerns and competitive threats.
Trailing returns across standard periods
Latest headlines on both assets
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →Celsius Holdings Inc engages in the development, marketing, sale, and distribution of functional calorie-burning beverages. It offers flavors including cola, orange, wild berry and lemon iced tea and non-carbonated flavors such as Raspberry Acai Green Tea and Peach Mango Green Tea under the Celsius brand name. The company distributes its products through direct-store-delivery distributors, as well as directly to retailers across various retail segments, including supermarkets, convenience stores, drug stores, nutritional stores, mass merchants, health clubs, spas, gyms, military, and e-commerce websites.
Read more on CELH →